Dr. Reddy's Laboratories Launches Novel Molecule 'Tegoprazan' in India

Dr. Reddy's Laboratories Ltd. announced the launch of the novel molecule 'Tegoprazan' in India under the brand name PCAB®. Tegoprazan is a next-generation potassium-competitive acid blocker indicated for the treatment of acid peptic diseases such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive Gastroesophageal Reflux Disease (NERD), and Gastric Ulcer. The molecule offers fast onset of action and prolonged gastric pH control, addressing a significant clinical need in India where acid peptic diseases affect approximately 38% of the population. This launch follows Dr. Reddy's exclusive partnership with South Korea-based HK inno.N Corporation in 2022 to commercialize Tegoprazan in India and select emerging markets. Tegoprazan is already approved in 21 countries and has completed Phase-III trials in the United States.